Residual tumor after the salvage surgery is the major risk factors for primary treatment failure in malignant ovarian germ cell tumors: A retrospective study of single institution by Lee, Chung Won et al.
RESEARCH Open Access
Residual tumor after the salvage surgery is the
major risk factors for primary treatment failure in
malignant ovarian germ cell tumors:
A retrospective study of single institution
Chung Won Lee
1, Min Jong Song
2, Sung Taek Park
3, Eun Young Ki
3, Sung Jong Lee
4, Keun Ho Lee
4, Ki Sung Ryu
1,
Jong Sup Park
3 and Soo Young Hur
3*
Abstract
Background: Malignant ovarian germ cell tumors are rare, and knowledge of their prognostic factors is limited,
with little available randomized data. This study was conducted to evaluate the clinicopathologic characteristics of
malignant ovarian germ cell tumors and to determine the association of their prognostic factors to primary
treatment failure.
Methods: The medical records of 57 patients with stages I to IV malignant ovarian germ cell tumor were
retrospectively reviewed, and their clinicopathologic and treatment-related data were collected and analyzed.
Results: The median age at the diagnosis was 23.3 years (range: 8-65 years), and the median follow-up period was
108 months (range: 48-205 months). The histological types of the tumors were immature teratoma (n = 24),
dysgerminoma (n = 20), endodermal sinus tumor (n = 8), mixed germ cell tumor (n = 4), and choriocarcinoma (n
= 1). 66.7% of the patients had stage I disease; 5.2%, stage II; 26.3%, stage III; and 1.8%, stage IV. After the initial
surgery, 49 patients (86%) received cisplatin-based chemotherapy. The five-year survival rate was 96.5%. There were
six primary treatment failures, with two of the patients dying of the disease, and the median time to the
recurrence was 8 months. The histological diagnosis (P < 0.0001), tumor stage (P = 0.0052), elevation of beta-hCG
(P=0.0134), operation methods (P=0.0006), and residual tumor after the salvage surgery (P < 0.0001) were
significantly associated with the risk of primary treatment failure in the univariate analysis. In the multivariate
analysis, the residual tumor after the salvage surgery was the only significant variable associated with primary
treatment failure (P = 0.0011, Hazard ratio = 29.046, 95% Confidence interval 3.832-220.181).
Conclusion: Most malignant ovarian germ cell tumors have excellent prognoses with primary treatment, and good
reproductive outcomes can be expected. Because primary treatment failure is associated with the residual disease
after the salvage surgery, knowledge of the presence or absence of this risk factor may be helpful in risk
stratification and individualization of adjuvant therapy in malignant ovarian germ cell tumors. Further large-scale
prospective studies to confirm these results should be performed.
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Malignant ovarian germ cell tumors (MOGCTs) are a
heterogeneous group of tumors that have several histo-
logically different types derived from primordial germ
cells of the embryonic gonad [1]. In contrast to epithe-
lial ovarian cancer (EOC), these tumors are rare cancers,
accounting for less than 5% of all ovarian malignancies,
and typically occur primarily in girls and young women
[2]. In addition, 50-75% of MOGCTs are stage I at their
diagnosis; and even in the advanced stage of the disease,
the survival rates are 60-80% [2-4]. In the past, radical
surgery was performed due to the presumed risk of
microscopic involvement of the grossly normal contral-
ateral ovary and uterus; but recent multimodality ther-
apy with initial fertility-sparing surgery and platinum-
based chemotherapy has improved the prognosis signifi-
cantly, even in patients with advanced diseases.
Because of the rare incidence of these tumors, however,
experience with MOGCTs is limited, with little available
randomized data and information on their management
in a sufficient number of patients [1, 4-5]. There is no
doubt that early-stage MOGCT patients have excellent
prognoses with standard treatment, whereas advanced
and recurrent tumors remain a challenge. In addition, the
fact that most MOGCTs occur in reproductive-age
women is of great importance to the treatment of the dis-
ease. Prognostic factors are very important because they
may influence the decision to perform less radical surgery
in the early stages of the disease without compromising
fertility and may be helpful in creating risk stratification
models for individualization of adjuvant therapies [4,6].
This study reports the experience of an institution in the
management of MOGCTs over a period of about 20
years. The aim of this study was to evaluate the clinico-
pathologic characteristics of MOGCTs and to determine
the association of their prognostic factors to their pri-
mary treatment failure.
Methods
After obtaining approval from the Institutional Review
Board (IRB), all women diagnosed with histologically
proven MOGCTs were identified using our institutional
medical database. Patients who were primarily treated
elsewhere and were referred to the authors’ institution
for adjuvant chemotherapy or salvage therapy after the
r e c u r r e n c eo ft h e i rd i s e a s ew e r ee x c l u d e d .T h em e d i c a l
records of the patients were retrospectively reviewed,
and data were collected regarding their demographics,
disease characteristics, management patterns, disease
recurrence, and survival.
The histological types of the disease were classified
according to the World Health Organization (WHO)
System [7], and the stages were assigned as described by
the International Federation of Gynecology and
Obstetrics (FIGO). All the patients underwent maximal
cytoreductive surgery as their primary treatment, and
depending on their pathologic results and operative
findings, some received adjuvant chemotherapy accord-
ing to institutional guidelines. The initial surgery was
considered a staging operation when peritoneal cytology,
multiple biopsies, infracolic omentectomy, and lympha-
denectomy were also performed. A fertility-sparing sur-
gery was defined as preservation of the uterus and at
least part of one ovary to preserve fertility. The duration
of the follow-up was calculated from the pathologic
diagnosis to the date of the last visit. The time to recur-
r e n c ew a sd e f i n e da st h ep e r i o df r o mt h el a s td a t eo f
primary treatment (the date of surgery or the date of
adjuvant chemotherapy) to the first observation of dis-
ease progression. The recurrence/progression free survi-
val and the time to recurrence were estimated using the
method of Kaplan and Meier, and the log rank test with
SPSS (Version 12.0; SPSS, Inc., Chicago, Ill) was used to
assess the statistical significance of the prognostic fac-
tors. Multivariate analysis was performed using Cox’s
regression analysis. P values that were less than 0.05
were considered statistically significant. All the P values
were two-sided.
Results
Clinicopathologic characteristics and treatment methods
Seventy-two women who were treated in the Division of
Gynecologic Oncology at Seoul St. Mary’sH o s p i t a l
between January 1990 and July 2009 were identified as
having had MOGCT. Among them, 57 patients received
primary treatment in the authors’ institution, and the
remaining 15 patients were primarily treated elsewhere
and were referred to the authors’ institution for adjuvant
chemotherapy (n = 8) or salvage therapy after the recur-
rence of their disease (n = 7). The clinicopathologic
characteristics and treatment methods of 57 patients are
summarized in Tables 1 and 2. The median age at the
diagnosis was 23.3 years (range: 8-65 years), and the
median follow-up period of the survivors was 108
months (range: 48-205 months). Most of the patients
were nulliparous (n = 45, 78.9%). The tumor size ranged
from 4 to 25 cm in the maximal diameter, and the
mean tumor diameter was 15.2 cm. The histological
types of the tumors were immature teratoma (n = 24),
dysgerminoma (n = 20), endodermal sinus tumor (EST)
(n = 8), mixed germ cell tumor (n = 4), and choriocarci-
noma (n = 1). Most of the tumors were unilateral (n =
51, 89.4%), but the histological types of bilateral tumors
were dysgerminoma (3/6, 50%), EST (2/6, 33.3%), and
mixed germ cell tumor (1/6, 16.7%). 66.7% of the
patients had stage I disease; 5.2%, stage II; 26.3%, stage
III; and 1.8%, stage IV. The alpha-fetoprotein (AFP)
levels were known for 46 patients, and two patients with
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levels that were higher than 100 ng/ml. Three patients
with mixed germ cell tumor who had elements of EST
also had elevated AFP levels. The beta-human gonado-
trophic hormone (hCG) was checked in 53 patients, and
was elevated in four patients with dysgerminoma, in
three with mixed germ cell tumor, and in one with
choriocarcinoma.
Regarding the surgery for the primary tumor, a ferti-
lity-sparing surgery was performed in 42 patients
(73.7%), a staging operation in 31 patients (54.4%).
Lymph node involvement was reported in 10 of the 31
patients who underwent the staging operation. Most of
the patients who underwent surgery had no residual dis-
ease (n = 47, 82.5%); but based on the pathologic results
and operative findings, stage I dysgerminoma or stage
Ia, grade 1 immature teratoma was observed without
postoperative adjuvant chemotherapy, and the patients
who had the other pathologic results and operative find-
ings were allowed to postoperative adjuvant chemother-
apy. Forty nine patients underwent postoperative
cisplatin-based chemotherapy, and the most common
regimen was etoposide and cisplatin (EP), followed by
bleomycin, etoposide, and cisplatin (BEP) (Table 2).
Eight of the patients had pelvic or abdominal residual
disease with a tumor diameter of less than 1 cm; one
patient had a 2 cm metastasis on his liver surface; and
the patient who was diagnosed with choriocarcinoma
had unresectable lung metastasis.
Prognostic factors associated with primary treatment
failure
After a median follow-up of 108 months (range: 48-205
months), there were six primary treatment failures, with
two patients dying of the disease, and the five-year sur-
vival rate was 96.5%. Recurrence was observed in five
patients (8.8%), and disease progression was observed in
one patient (1.8%). The time to recurrence ranged from
4 to 12 months, and the median time to recurrence was
8 months. The detailed clinical features and outcomes
of the patients who experienced primary treatment fail-
ure are summarized in Table 3.
The histological diagnosis (P < 0.0001), tumor stage (P
= 0.0052), elevation of beta-hCG (P=0.0134), operation
methods (P=0.0006), and residual tumor after the sal-
vage surgery (P < 0.0001) were significantly associated
with the risk of primary treatment failure in the univari-
ate analysis (Tables 1 and 2). The recurrence/progres-
sion-free survival rate was 100% for dysgerminoma (20/
20), 95.8% for immature teratoma (23/24), 75.0% for
EST (2/8), 50.0% for mixed germ cell tumor (2/4), and
0% for choriocarcinoma (P <0 . 0 0 0 1 ) .T h er a t eo fp r i -
mary treatment failure was 1.8% for women in stages I
a n dI I ,a n d8 . 8 %f o rw o m e ni ns t a g e sI I Ia n dI V( P =
0.0052). Complete tumor resection was performed on 47
patients and showed a lower recurrence rate than
incomplete resection (P < 0.0001). The age, volume of
ascites, elevation of AFP, treatment modalities, and che-
motherapy regimen did not affect the primary treatment
failure. In the multivariate analysis, the residual tumor
after the salvage surgery was the only significant variable
associated with the primary treatment failure with
respect to the MOGCTs (P = 0.0011, Hazard ratio [HR]
= 29.046, 95% Confidence interval [CI] 3.832-220.181).
The Kaplan-Meier estimate of the recurrence/progres-
sion free survival based on the residual tumor after the
salvage surgery (no residual mass vs. ≤ 1c mo fr e s i d u a l
mass vs. > 1 cm of residual mass) is shown in Figure 1.
The one-year recurrence/progression-free survival rate









< 20 26(45.6) 2(3.5) 0.1177
20-40 28(49.1) 3(5.3)
> 40 3(5.3) 1(1.8)
Histological diagnosis
Dysgerminoma 20(35.1) 0(0.0) < 0.0001










Dysgerminoma 20(35.1) 0(0.00) 0.0716
Non-dysgerminoma 37(64.9) 6(10.5)
Stage





Volume of ascites, cc
< 100 33(57.9) 2(3.5) 0.1277
≥ 100 24(42.1) 4(7.0)
Elevated AFP, ng/ml
(n = 46)
< 100 36(78.3) 4(8.7) 0.4089
≥ 100 10(21.7) 2(4.4)
Beta-hCG (n = 53)
Normal 45(84.9) 3(5.7) 0.0134
Elevated 8(15.1) 3(5.7)
AFP, alpha-fetoprotein; hCG, human gonadotrophic hormone.
a Comparison between two groups.
b Comparison between stage I-II and stage III-IV.
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surgery was 97.8%, and only 62.5% for the patients with
≤ 1 cm of residual mass, and 0% for the patients with >
1 cm of residual mass.
During the follow-up period, 14 patients reported
attempting to conceive post-treatment, and seven
patients had 10 successful pregnancies with 10 full-term
live births. All these seven women had received adjuvant
EP or BEP chemotherapy. There is no evidence of birth
defects or other disabilities in any of the offspring. One
patient diagnosed to stage IIIc EST and received 4 cycles
of EP chemotherapy had acute myeloid leukemia (AML)
Table 2 Analyses of treatment-related variables associated with recurrence/progression in MOGCTs




Surgery only 8(14.0) 1(1.8) 0.4342
Surgery + chemotherapy 49(86.0) 5(8.8)
Operation methods
Fertility sparing 42(73.7) 1(1.8) 0.0006
Cystectomy without staging op. 1(1.8) 0(0.0)
USO without staging op. 20(35.1) 0(0.0)
USO with staging op. 21(36.8) 1(1.8)
Non-fertility sparing 15(26.3) 5(8.8)
Hysterectomy + BSO without staging op. 5(8.8) 0(0.0)
Hysterectomy + BSO with staging op. 10(17.5) 5(8.8)
Chemotherapy regimens (n = 49)





None 47(82.5) 1(1.8) < 0.0001
≤ 1 cm 8(14.0) 3(5.3)
> 1 cm 2(3.5) 2(3.5)
USO, unilateral salpingo-oophorectomy; BSO, bilateral salpingo-oophorectomy; BEP, bleomycin, etoposide, and cisplatin; EP, etoposide and cisplatin; VBP,
vinblastine, bleomycin, and cisplatin.
Table 3 Summary of clinicopathologic features, treatment, and outcome of those who failed primary treatment
Pt’s
ID












CR 4 Brain EMA-CO
chemo.
DOD




CR 11 PAN BEP chemo NED
at age 33





CR 12 Mesentery EP chemo NED
at age 33
4 19 EST/Stage IIIa TAH + BSO
+ staging op
+ CP chemo.
CR 7 Mesentery EP chemo. NED
at age 29
5 29 EST/Stage IIIc TAH + BSO
+ staging op
+ EP chemo.









Progressi-on Liver Cisplatin + Paclitaxel
chemo.
DOD
TAH, total abdominal hysterectomy; BSO, bilateral salpingo-oophorectomy; USO, unilateral salpingo-oophorectomy; EMA-CO, etoposide, methotraxate,
actinomycin-D, vincristine, and cyclophosphamide; BEP, bleomycin, etoposide, and cisplatin; EP, etoposide and cisplatin; CP, cisplatin and cyclophophamide; VBP,
vinblastine, bleomycin, and cisplatin; CR, complete remission; PAN, paraaortic lymph node; DOD, died of disease; NED, no evidence of disease.
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etoposide (100 mg/m
2 on days 1-5), cisplatin (100 mg/
m
2 on days 1), and a cumulative dose of etoposide was
3200 mg/m
2, but the patient received allogenic bone
marrow transplantation, and has no evidence of disease
at present.
Discussion
The introduction of adjuvant platinum-based che-
motherapy in cytoreductive surgery has improved the
prognosis of MOGCTs, and the overall disease-free sur-
vival rate is more than 95% [8]. The occurrence of most
MOGCTs in reproductive-age women requires special
consideration, however, as it means most MOGCT
patients must be treated with a fertility-sparing modality
that does not compromise survival.
To accomplish this therapeutic intent, the most impor-
tant thing to do is risk stratification of the diseases
according to their prognosis. With their limited number
of cases, however, virtually no randomized controlled
trials have been conducted on MOGCTs, and several dif-
ferent, inconsistent prognostic factors have been reported
in retrospective studies. A study by Lai et al. analyzed the
prognostic factors of 93 MOGCTs, and the authors sug-
gested that the histology (dysgerminoma vs.n o n - d y s g e r -
minoma, P < 0.0001) and the FIGO stage (I-II vs.I I I - I V ,
P = 0.001) were significantly associated with treatment
failure, whereas the histology (dysgerminoma vs.n o n -
dysgerminoma, P < 0.0004), the residual tumor after the
salvage surgery (≥ 1c mvs.<1c m ,P = 0.0014), and the
salvage high-dose chemotherapy failure (P = 0.0405) sig-
nificantly influenced the overall survival [9]. In a more
recent study, Lee et al. reported that the age (≤ 40 years
vs. > 40 years, P = 0.031) and the FIGO stage (I-II vs.I I I -
IV, P=0.032) significantly predicted recurrence in 196
Korean women with MOGCTs [4]. In the study of Muru-
gaesu et al., univariate and multivariate analyses of 113
MOGCTs demonstrated the importance of tumor mar-
kers (AFP and beta-hCG) (relative risk [RR], 3.90; P =
0.009) and the initial stage of the disease (RR, 5.96; P =
0.03) as predictors of overall survival, whereas the age at
the diagnosis had no prognostic value [10]. In still
another study, Kumar et al. suggested lymph node invol-
vement as an independent predictor of poor survival,
with a hazards ratio of 2.87 (95% CI 1.439-5.725; P <
0.05) [6]. Several studies on non-dysgerminomatous
ovarian germ cell tumors (NDOGCTs) have also been
reported [11-14]. In these studies, an early stage [11-13],
minimal residual tumor after the initial surgery [11-13],
less than 100 cc of ascites [11,12], platinum-based che-
motherapy [11,12], an AFP level less than 1,000 kU/L,
and a non-EST histology were found to be significantly
related to a more favorable prognosis [14]. In conclusion,
taking into account the results from largest series
reported on MOGCTs, stage, residual disease, histologi-
cal type, elevation of tumor markers, and chemothera-
peutic regimen seem to be recognized as prognostic
factors for patients with MOGCT. In this study, the his-
tological diagnosis (P < 0.0001), tumor stage (P < 0.0001),
elevation of beta-hCG (P=0.0134), operation methods
(P=0.0006), and residual tumor after the salvage surgery
(P < 0.0001) were found to be significantly associated
with the risk of primary treatment failure in the univari-
ate analysis. In the multivariate analysis, however, the
residual tumor after the salvage surgery was the only sig-
nificant variable associated with primary treatment fail-
ure for MOGCTs (P = 0.0011, HR = 29.046, 95% CI
3.832-220.181), whereas the correlation of the other fac-
tors could not be proven (data not shown). Significant P-
value with a very wide confidence interval of this factor
may have been caused by the fact that the majority of
MOGCTs are so early staged that maximal cytoreductive
surgery can be performed in most cases. In other words,
it may have been caused by relatively small size of the
group with residual lesions due to the excellent surgical
outcome of the MOGCTs. Type of operation (fertility
sparing vs. non-fertility sparing operation) was found to
be significantly associated with the risk of primary treat-
ment failure in the univariate analysis (P=0.0006), but
not in the multivariate analysis (P = 0.1493). The major
reasons to perform a non-fertility sparing operation
instead of a fertility sparing operation in this study are
the willingness of patients to preserve fertility and the
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Figure 1 The recurrence/progression free survival based on the
residual tumor after the salvage surgery. Figure 1 presents the
Kaplan-Meier estimate of the recurrence/progression free survival
based on the residual tumor after the salvage surgery (no residual
mass vs. ≤ 1 cm of residual mass vs. > 1 cm of residual mass). The
one-year recurrence/progression-free survival rate of the patients
with no residual tumor after their salvage surgery was 97.8%, and
only 62.5% for the patients with ≤ 1 cm of residual mass, and 0%
for the patients with > 1 cm of residual mass.
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expected to have poor prognostic outcome according to
the authors’ clinical experiences, more radical operations
may be performed in this group. Therefore, patients who
had non-fertility sparing operations seemed to have poor
prognosis in the univariate analysis, but type of operation
was not actually significant in the statistics.
The principles of cytoreductive surgery in epithelial
ovarian cancer, i.e., resection of as much gross tumor as
possible, have been applied to the management of
MOGCTs. Two Gynecologic Oncology Group (GOG)
studies indicated that patients with unresectable or
incompletely resected MOGCTs had fewer chances of
full remission after chemotherapy than patients with
minimal residual disease [15,16]. Both studies had lim-
ited sample sizes, however, and the chemotherapy regi-
mens that they employed (VAC, vincristine, actinomycin
D, and cycolphosphamide; and PVB, cisplatin, vinblas-
tine, and bleomycin, respectively) are not the most
active regimens at present [8]. The role and extent of
cytoreductive surgery remain controversial despite its
routine use, unless the randomized data can prove the
therapeutic advantages. Nevertheless, taking into
account the results of many series [9,11-13,15,16] and
the chemotherapy-sensitive nature of the disease, an
adequate attempt at maximal cytoreduction without
compromising future fertility seems a reasonable surgi-
cal approach at present. Many studies have shown that
fertility-sparing surgery is a safe, reasonable treatment
option that does not compromise survival, but support
for such an approach shall arise not from prospective
randomized trials but from experiential evidence. Ger-
shenson et al., and Kurman et al. did not observe wor-
sening of the prognosis associated with unilateral
salpingo-oophorectomy (USO) in MOGCT patients,
compared to BSO [2,17]. Tewari et al. reported that the
prognoses of 46 patients with MOGCTs who underwent
USO and postoperative systemic chemotherapy were
excellent (five-year survival rate, 93%) [18]. In this study,
of the 42 patients with MOGCTs who underwent ferti-
lity-sparing surgery, only one grade I immature teratoma
patient who did not undergo postoperative adjuvant
chemotherapy had a recurrence in her para-aortic
lymph node, and was successfully salvaged with BEP
chemotherapy.
The introduction of multimodality therapy with initial
surgery and subsequent chemotherapy has dramatically
improved the prognosis of patients with MOGCTs. The
evolution of systemic therapy of MOGCTs has paral-
leled the advances made in the treatment of testicular
germ cell tumors [1]. Lessons learned from randomized
clinical trials in testicular cancer cases have been applied
to the much fewer ovary tumors. VAC was the first effi-
cient chemotherapy regimen to achieve about 50%
remission in advanced stages, and up to 85% in early
stages in the treatment of NDOGCTs [15,19]. The
inclusion of cisplatin in the systemic therapy of
MOGCTs (PVB and BEP) has proven to yield a better
chance of cure of up to 60-80%, even with incompletely
resected advanced-stage tumors [8,16,20-23]. The largest
prospective study of BEP as adjuvant therapy was per-
formed by GOG [23]. In the study, of 93 patients who
had MOGCT and underwent three courses of BEP post-
operatively, 89 patients have remained free of the dis-
ease (89/93, 96%). A multi-institutional trial reported
that the BEP regimen showed equal efficacy and less
toxicity than the PVB regimen in patients with testicular
cancer [24], and therefore, the BEP regimen is regarded
as the standard regimen for first-line chemotherapy of
MOGCTs. In this study, the most common chemothera-
peutic regimen selected was EP (n = 28) rather than
BEP (n = 8). While a randomized study has found that
three cycles of the BEP regimen are superior to the EP
regimen in the case of testicular cancer (relapse-free
survival rate, 84% vs. 69%, P = 0.03) [25], because of the
authors’ terrible experiences in fatal pneumonitis asso-
ciated with bleomycin, we selected the EP regimen for
most of their patients with MOGCTs. As mentioned,
the chemotherapy regimen was not influenced by the
prognosis of MOGCTs, and the EP regimen was as
highly effective as the BEP regimen in this study.
Given the prognosis and age of most of the patients,
the important things to consider are the long-term side-
effects of chemotherapy. The most serious potential
long-term forms of toxicity of chemotherapy are second-
ary malignancies, foremost of which is acute non-lym-
phoblastic leukemia. This is a well-known complication
of relatively long-term alkylating agent therapy. In the
study of Pedersen-Bjergaard et al., they described the
mean cumulative risk of leukemic complications in 212
patients with germ cell tumors treated with BEP
increased steadily from 15 months after start of etopo-
side and reached a mean of 4.7% at 5.7 years, and com-
pared with the risk in the general population, the
relative risk of overt leukemia was 336 [26]. The authors
encountered a case of AML development in one patient
19 months after she started the etoposide-containing
regimen (1/36, 2.8%), but the patient underwent allo-
genic bone marrow transplantation, and has no evidence
of disease at present. Another important issue is the
impact of chemotherapy on the reproductive function.
According to a review of Gershenson, 27 of 40 patients
who underwent fertility-sparing surgery maintained reg-
ular menses after their completion of chemotherapy, 33
had regular menstruation at the time of their follow-up,
and of the 16 patients who had attempted to become
pregnant since completing the chemotherapy, 11 deliv-
ered 22 healthy infants without major birth defects [27].
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reported that of 64 patients who underwent fertility-
sparing surgery, 38 attempted conception and 29
became pregnant (76%) with no congenital anomalies
[28]. In this study, of the 14 patients who attempted to
conceive after their treatment, 50% had successful preg-
nancies with no evidence of birth defects or other dis-
abilities in any of their offspring.
This report was limited by its small number of cases
d u et ot h er a r i t yo ft h ed i s e a s e ,a n dt h er e t r o s p e c t i v e
study design. This report has highlighted, however, the
current state of clinicopathology, management, and
prognosis of MOGCTs. In summary, this report showed
that most MOGCTs have excellent prognosis with pri-
mary treatment, and good reproductive outcomes can
be expected for them. Because the primary treatment
failure is associated with the residual disease after the
salvage surgery, knowledge of the presence or absence
of this risk factor may be helpful in risk stratification
and individualization of adjuvant therapy in MOGCTs.
Further large-scale prospective studies to confirm these
results are needed.
Conclusions
This study was undertaken to evaluate the clinicopatho-
logic characteristics of MOGCTs and to determine the
association of their prognostic factors to primary treat-
ment failure in female patients. Residual tumor after the
s a l v a g es u r g e r yw a sf o u n dt ob et h eo n l yr i s kf a c t o rf o r
primary treatment failure of MOGCTs, but most
MOGCTs have excellent prognosis with primary treat-
ment, and good reproductive outcomes can be expected
for them. Further studies are required to determine the
most effective management strategies in patients with
these risk factors for primary treatment failure.
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